Oncoinvent ASA
LSE: 0RU5.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Oystein Soug
- Employees
- 36
- Headquarters
- Oslo, Norway
- IPO year
- 2017
- Market cap
- NOK 1.8B
- Website
- https://www.oncoinvent.com
Loading 0RU5…
Loading profile data…Frequently asked questions about 0RU5
What does Oncoinvent ASA (0RU5.L) do?
Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and...
Where does 0RU5.L trade?
Oncoinvent ASA (0RU5.L) trades on the London Stock Exchange.
What sector is 0RU5.L in?
Oncoinvent ASA (0RU5.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Oncoinvent ASA?
Oystein Soug is the chief executive officer of Oncoinvent ASA (0RU5.L).
Where is Oncoinvent ASA headquartered?
Oncoinvent ASA is headquartered in Norway.
Does 0RU5.L pay a dividend?
Oncoinvent ASA (0RU5.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0RU5.L go public?
Oncoinvent ASA (0RU5.L) completed its initial public offering in 2017.